Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Commercial Operations | 84.2 | 67.9 | 53.6 | 37.5 | | |
| Fee-per-use and other | | | | | 5.9 | |
| TriPath Oncology | 1.8 | 0.6 | 0.1 | | | |
| Instruments | | | | | 10.2 | |
| Other | | | | | 10.9 | |
| Total revenues | 86.0 | 68.5 | 53.8 | 37.5 | 27.0 | 32.7 |
| Revenue growth [+] | 25.5% | 27.4% | 43.4% | 38.7% | -17.3% | |
| Commercial Operations | 24.0% | 26.5% | 43.1% | | | |
| TriPath Oncology | 181.0% | 382.7% | | | | |
| Cost of goods sold | 26.0 | 21.2 | 18.4 | 14.9 | 13.1 | 16.1 |
| Gross profit | 59.9 | 47.3 | 35.4 | 22.6 | 13.9 | 16.5 |
| Gross margin | 69.7% | 69.0% | 65.8% | 60.2% | 51.5% | 50.6% |
| Selling, general and administrative [+] | 38.0 | 31.8 | 30.0 | 30.8 | 28.8 | 23.9 |
| Sales and marketing | 24.4 | 18.6 | 18.3 | 19.9 | 18.7 | 5.7 |
| General and administrative | 13.6 | 13.1 | 11.7 | 10.9 | 10.1 | 18.1 |
| Research and development | 12.4 | 11.3 | 8.9 | 7.5 | 5.9 | 8.8 |
| Other operating expenses | 3.4 | 3.9 | 5.4 | 2.7 | 2.0 | 0.8 |
| EBITDA [+] | 11.5 | 5.3 | -4.6 | -14.6 | -18.8 | -10.3 |
| EBITDA growth | 117.7% | -215.3% | -68.8% | -22.2% | 82.8% | |
| EBITDA margin | 13.3% | 7.7% | -8.5% | -39.0% | -69.6% | -31.5% |
| Depreciation | 4.4 | 4.1 | 3.5 | 3.0 | 3.1 | 5.9 |
| EBITA | 7.1 | 1.2 | -8.1 | -17.7 | -21.9 | -16.2 |
| EBITA margin | 8.2% | 1.7% | -15.1% | -47.1% | -80.9% | -49.5% |
| Amortization of intangibles | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| EBIT [+] | 6.2 | 0.3 | -8.9 | -18.5 | -22.7 | -17.0 |
| EBIT growth | 1750.0% | -103.7% | -51.7% | -18.5% | 33.7% | |
| EBIT margin | 7.2% | 0.5% | -16.6% | -49.3% | -84.0% | -52.0% |
| Interest income, net [+] | 0.6 | 0.3 | 0.4 | 0.4 | 1.0 | 1.3 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.6 | 1.3 | |
| Interest income | 0.6 | 0.3 | 0.4 | 1.0 | 2.3 | 1.3 |
| Other income (expense), net | | | | | | -1.7 |
| Pre-tax income | 6.8 | 0.6 | -8.5 | -18.1 | -21.7 | -17.4 |
| Income taxes | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 6.5 | 0.6 | -8.5 | -18.1 | -21.7 | -17.4 |
| Net margin | 7.6% | 0.9% | -15.9% | -48.2% | -80.2% | -53.2% |
| |
| Basic EPS [+] | $0.17 | $0.02 | ($0.23) | ($0.48) | ($611.27) | ($596.11) |
| Growth | 750.0% | -108.7% | -52.1% | -99.9% | 2.5% | |
| Diluted EPS [+] | $0.17 | $0.02 | ($0.23) | ($0.48) | ($611.27) | ($596.11) |
| Growth | 750.0% | -108.7% | -52.1% | -99.9% | 2.5% | |
| |
| Shares outstanding (basic) [+] | 38.2 | 30.3 | 37.1 | 37.6 | 0.0 | 0.0 |
| Growth | 26.4% | -18.5% | -1.4% | 106008.0% | 21.7% | |
| Shares outstanding (diluted) [+] | 38.2 | 30.3 | 37.1 | 37.6 | 0.0 | 0.0 |
| Growth | 26.4% | -18.5% | -1.4% | 106008.0% | 21.7% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|